2026 predictions: historic FDA shift, plausible mechanisms, bespoke tx, RFK Jr., biotechs, state AGs, peptides, embryos The Niche Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Reclassification 2026 Amanecia Health Orthopedic Use of BPC 157 Sports Med Review